- Viking Therapeutics is making significant strides in obesity treatment with its drug VK2735.
- Analysts suggest a substantial potential upside for VKTX stock, with an average price target over 260% higher than its current value.
- The company's financials, particularly in R&D, reflect its commitment to advancing its clinical trials.
Viking Therapeutics (VKTX, Financial) is strategically progressing with its promising obesity treatment, VK2735. The company is gearing up for the Phase 3 trials of the subcutaneous version, set to begin in Q2 2025, while the oral version has successfully completed enrollment for Phase 2.
Financial Overview
In the first quarter of 2025, Viking Therapeutics reported an increase in research and development expenses, which climbed to $41.4 million. This investment underscores the company's dedication to its drug development pipeline, although it did contribute to a net loss of $45.6 million. These figures highlight the financial challenges and commitments involved in pioneering cutting-edge treatments.
Wall Street Analysts' Forecast
Looking at Wall Street's outlook, 15 analysts have provided one-year price targets for Viking Therapeutics Inc (VKTX, Financial), with an average target price of $93.13. The estimates vary significantly, with a high mark of $125.00 and a low of $30.00, suggesting a potential upside of 261.12% from the current stock price of $25.79. Investors interested in a detailed breakdown of these estimates can visit the Viking Therapeutics Inc (VKTX) Forecast page.
Consensus among 18 brokerage firms places Viking Therapeutics Inc's (VKTX, Financial) average brokerage recommendation at 1.7, denoting an "Outperform" rating. This scale ranges from 1, indicating a Strong Buy, to 5, which suggests a Sell. Such a favorable rating reflects confidence in the company's strategic direction and potential market performance.
